M28 Capital Management LP
M28 Capital Management LP reported 9 US-listed holdings worth $47.2 million in its 13F for the quarter ended 30 June 2026, filed 13 August 2026. Its largest: Wave Life Sciences Ltd (56.5%), Invivyd Inc. (17.1%) and TG Therapeutics, Inc. (10.3%). Against the quarter before, it opened 0 positions, added to 0, trimmed 0 and sold out of 0.
The 9 largest of its 9 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned -19.1% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Wave Life Sciences Ltd WVE | 4.6M | $26.7 million | 56.53% | no change |
| Invivyd Inc. IVVD | 9.2M | $8.1 million | 17.11% | no change |
| TG Therapeutics, Inc. TGTX | 88.4K | $4.9 million | 10.29% | no change |
| Arrowhead Pharmaceuticals, Inc. ARWR | 36.9K | $3.0 million | 6.37% | no change |
| Fractyl Health Inc. GUTS | 1.9M | $1.5 million | 3.13% | no change |
| Proqr Thrapeutics N V PRQR | 599.8K | $1.1 million | 2.37% | no change |
| Silence Therapeutics PLC SLN | 101.2K | $1.1 million | 2.36% | no change |
| Rocket Pharmaceuticals Inc. RCKT | 210.9K | $721,179 | 1.53% | no change |
| Curis Inc. CRIS | 284.9K | $148,741 | 0.32% | no change |